I’ve worked for many years on HIV infection, focusing on innate immune responses against the virus at first, then on antiviral resistance to HAART (Nucleoside inhibitors, Integrase inhibitors, entry inhibitors). I’ve also investigated virus evolution under selective pressure, in terms of viral fitness and of viral reservoirs. I’ve always been very interested in viral determinants dictating transmissibility and cytotoxicity in vitro or pathogenicity in vivo.
I worked some time on genomic APOBEC mutations in inflammatory diseases and in cancer.
When the COVID-19 pandemic burst, I came back to virology, isolating and characterizing the variants, developing various neutralization assays based on replicating virus, pseudotypes or ELISA (surrogate viral neutralization assay) as well as PCR detection assays. I joined the National Reference Center of Respiratory Infection Viruses as of February 2024, combining viral typing and characterization to epidemiological surveillance for the main respiratory viruses (InfluenzaA and B, SARS-CoV-2, Respiratory Syncytial Virus (RSV), Metapneumoviruses, Rhinoviruses/Enteroviruses, ParainfluenzaViruses) as well as for potential zoonotic viruses.